<DOC>
	<DOCNO>NCT00002163</DOCNO>
	<brief_summary>To evaluate benefit add 1592U89 current antiretroviral therapy AIDS dementia complex ass safety tolerance treatment regimen .</brief_summary>
	<brief_title>A Phase III , Randomized , Double-Blind , Multicentre Study Evaluate Safety Efficacy 1592U89 Patients With AIDS Dementia Complex</brief_title>
	<detailed_description>Patients must stable antiretroviral treatment least 6 week prior study entry stratify depend whether regimen contains zidovudine ( ZDV ) . Each stratum randomize separately receive 1592U89 placebo 12 week . For subsequent 40 week , open-label 1592U89 offer .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>AIDS Dementia Complex</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . Evidence HIV associate dementia . Been stable antiretroviral treatment minimum 6 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Debilitated result HIV disease , associate illness therapy investigator determines able complete 12 week randomize dosing period . Memorial SloanKettering ( MSK ) score &gt; = 3 dementia . Confounding neurological disease may interfere interpretation neurological neurophysical assessment . Malabsorption syndrome gastrointestinal dysfunction render unable take oral medication . Chronic disease diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction , etc. , investigator 's opinion would compromise safety patient . Symptomatic AIDSdefining opportunistic infection responsive therapy . Concurrent Medication : Excluded : Treatment cytotoxic chemotherapeutic agent within first 12 week study . Treatment nerve growth factor within first 12 week study . The use narcotic analgesic , sedative , benzodiazepine , antidepressant , antipsychotic agent psychoactive drug would interfere assessment neurological neurophysical status patient . Use stavudine ( d4T ) first 12 week study . Immunomodulating agent ( except GM/GCSF epoietin ) . Psychoactive drug ( investigator 's discretion ) . Concurrent Treatment : Excluded : Treatment radiation therapy within first 12 week study . NOTE : With exception local treatment Kaposi 's sarcoma . Patients follow prior condition exclude : Previous neurological disease unrelated HIV infection . History clinically apparent hepatitis within last 6 month . History clinically apparent pancreatitis last 6 month . Prior Medication : Excluded : Treatment cytotoxic chemotherapeutic agent within 1 month entry . Participation investigational antiretroviral trial within past 3 month . HIV vaccine within past 3 month . Treatment immunomodulating agent systemic corticosteroid , interleukin , thalidomide , anticytokine agent , antioxidant interferon within 1 month study entry . Nerve growth factor . Prior Treatment : Excluded : Treatment radiation therapy within 1 month entry . NOTE : With exception local treatment Kaposi 's sarcoma . Risk Behavior : Excluded : Current alcohol illicit drug use may interfere patient 's ability comply study protocol . Required : Stable antiretroviral treatment ongoing minimum 6 week prior study entry , may may include ZDV . Required : Stable antiretroviral treatment minimum 6 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS Dementia Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>